Combined group A streptococcus preparation (sapylin) and cisplatin for malignant peritoneal effusion.
- Author:
Jing PAN
1
Author Information
- Publication Type:Journal Article
- MeSH: Adjuvants, Immunologic; administration & dosage; Adult; Aged; Antineoplastic Agents; administration & dosage; Ascitic Fluid; pathology; Bacterial Proteins; administration & dosage; Biological Products; administration & dosage; Cisplatin; administration & dosage; Combined Modality Therapy; Female; Humans; Immunologic Factors; administration & dosage; Injections, Intraperitoneal; Male; Middle Aged; Ovarian Neoplasms; pathology; therapy; Peritoneal Neoplasms; secondary; therapy; Stomach Neoplasms; pathology; therapy; Streptococcus pyogenes; chemistry
- From: Chinese Journal of Oncology 2005;27(7):442-444
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect of Group A streptococcus preparation (sapylin) combined with cisplatin on the malignant peritoneal effusion in patients with advanced cancer.
METHODSSixty advanced cancer patients with large amount of peritoneal effusion were divided into two groups: sapylin + cisplatin (DDP) group (30 patients) and control group (DDP alone, 30 cases). All the chemotherapeutic agents were injected intraperitoneally through a catheter.
RESULTSIn sapylin + cisplatin(DDP) group, 11 (36.7%) patients showed CR and 16 (53.3%) PR. The overall response rate (CR + PR) was 90.0%. Those of DDP alone group were 16.7% and 46.7%, the overall response rate was 63.3%. The main adverse effects were fever, nausea, and vomiting.
CONCLUSIONCombined Group A streptococcus preparation (sapylin) and cisplatin is more effective than cisplatin alone for the malignant peritoneal effusion in patients with advanced cancer, and the adverse effects are tolerable.
